16189-69-8Relevant articles and documents
An Inhibitor of the Interaction of Survivin with Smac in Mitochondria Promotes Apoptosis
Park, Seong-Hyun,Shin, Insu,Park, Sang-Hyun,Kim, Nam Doo,Shin, Injae
, p. 4035 - 4041 (2019)
Herein we report the first small molecule that disrupts the survivin-Smac interaction taking place in mitochondria. The inhibitor, PZ-6-QN, was identified by initially screening a phenothiazine library using a fluorescence anisotropy assay and then conducting a structure–activity relationship study. Mutagenesis and molecular docking studies suggest that PZ-6-QN binds to survivin similarly to the known Smac peptide, AVPI. The results of the effort also show that PZ-6-QN exhibits good anticancer activity against various cancer cells. Moreover, cell-based mechanistic studies provide evidence for the proposal that PZ-6-QN enters mitochondria to inhibit the survivin-Smac interaction and promotes release of Smac and cytochrome c from mitochondria into the cytosol, a process that induces apoptosis in cancer cells. Overall, the present study suggests that PZ-6-QN can serve as a novel chemical probe for study of processes associated with the mitochondrial survivin-Smac interaction and it will aid the discovery of novel anticancer agents.
Phenothiazines nitric oxide donor, its preparation and use
-
Paragraph 0047-0050; 0051-0053, (2018/04/20)
The invention discloses a kind of phenothiazine-containing nitric oxide donor compounds with the structure of a formula I. In the formula I, n is equal to 0, 1 or 2, R1 is hydrogen, halogens, C1-C4 branched or linear alkyl, or halogenated C1-C4 branched or linear alkyl, and R2 is hydrogen or C1-C4 branched or linear alkyl. The invention also discloses a preparation method of the compounds, and discloses a pharmaceutical composition taking the compounds as an active composition, and application of the compounds as anti-tumor medicines, especially to prepare medicines for treating breast cancer, lung cancer and stomach cancer.
Reengineered tricyclic anti-cancer agents
Kastrinsky, David B.,Sangodkar, Jaya,Zaware, Nilesh,Izadmehr, Sudeh,Dhawan, Neil S.,Narla, Goutham,Ohlmeyer, Michael
supporting information, p. 6528 - 6534 (2015/10/05)
The phenothiazine and dibenzazepine tricyclics are potent neurotropic drugs with a documented but underutilized anti-cancer side effect. Reengineering these agents (TFP, CPZ, CIP) by replacing the basic amine with a neutral polar functional group (e.g., RTC-1, RTC-2) abrogated their CNS effects as demonstrated by in vitro pharmacological assays and in vivo behavioral models. Further optimization generated several phenothiazines and dibenzazepines with improved anti-cancer potency, exemplified by RTC-5. This new lead demonstrated efficacy against a xenograft model of an EGFR driven cancer without the neurotropic effects exhibited by the parent molecules. Its effects were attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling.